1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Combination Inhalers for Upper Airway Diseases : Products, Markets and Forecasts

Analyzing the Growth of Dual Therapy Inhalers

Combination inhalers – oral inhalers containing two drugs that complement the therapeutic actions of one another – have seen a significant increase in development activity and product proliferation in the past five years. Growth is being driven by improved patient experience as derived from ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated – Asthma and COPD - both of which are forecast to grow at impressive rates for the remainder of the decade.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

Report Highlights

- Analyzes the market for combination (dual drug) oral inhalers
- Assesses oral inhalation device technology for delivering multiple drugs, and evaluates product technology issues and evolving market factors
- Provides detailed assessments of combination drug inhalers, their growth prospects and market potential
- Evaluates development-stage dual therapy inhalers and assesses likely market entry timelines
- Provides market data and forecasts for dual drug oral inhaler products to 2022
- Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Table Of Contents

Combination Inhalers for Upper Airway Diseases : Products, Markets and Forecasts
Executive Summary
Orally Inhaled Corticosteroid Market Overview
The Upper Respiratory Therapeutics Marketspace
Therapeutic Targets for Combination Inhalers
Competing Drug Treatments
Demand Drivers
Technology Factors
Competitive Landscape
Asthma Market Risks and Opportunities
Global Patient Demographics
Regional Market Drivers
The Growing Therapeutic Need
Inhaler Technologies for Delivering Combination Therapies
Dry Powder Inhalers
DPI Formulation Technology
Characteristics and Parameters
DPI Excipients and Packaging
Metered Dose Inhalers
MDI Device Selection Criteria
Ease-of-Use Factors
Nebulizers
Combination Inhalers - Product Analysis, Market Data and Forecasts
Albuterol/Ipratropium (Nebulizer)
Albuterol/Ipratropium (MDI)
Generic Albuterol/Ipratropium Solution
Fluticasone/Vilanterol (DPI)
Fluticasone/Salmeterol (MDI)
Fluticasone/Salmeterol (DPI)
Budesonide/Formoterol (MDI)
Formoterol/Mometasone (MDI)
Umeclidinium/Vilanterol (DPI)
Development-stage Combination Inhalers
Dry Powder Formulations
Metered Dose Formulations
Nebulized Solutions
Therapeutic Market Assessment
Asthma
Demand Factors
Regional Market Factors
COPD
Demand Factors
Regional Market Factors
Market Factors
Regulatory Issues
Patient Compliance
Prescribing Trends
Healthcare Economics
Regional Market Factors
Connected Devices
Market Sector Company Profiles

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Pulmonary Arterial Hypertension (PAH) Therapeutics - Pharmaceuticals

Global Pulmonary Arterial Hypertension (PAH) Therapeutics - Pharmaceuticals

  • $ 4500
  • Industry report
  • January 2017
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH) Therapeutics in US$ Million. The Global market is analyzed by the following Drug Class and Brands: Endothelin Recepto ...

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

  • $ 2500
  • Industry report
  • December 2016
  • by Infiniti Research Limited

About Human Respiratory Syncytial Virus Drugs Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages ...

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016" provides an overview of ...

Tygacil -drug Insights, 2017

January 2017 $ 1000

Download Unlimited Documents from Trusted Public Sources

Related Market Segments :

Respiratory Treatment

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.